– USA, CA – Probius, a deep tech company bridging the data gap between biology and AI, today announced the elections of John MacWilliams and Janis Naeve to its Board of Directors.
“The strength brought by these two leaders comes at a fascinating time for Probius,” said CEO, Emmanuel Quevy. “Our commercialization will benefit greatly from Janis’ guidance within the biotechnology market and for biochemical applications. John’s insights into the transformational impact that high-fidelity data can have will help fuel the AI revolution from discovery to clinical applications.”
About John J. MacWilliams
In addition to his roles at LLNL and with President Biden’s administration, John J. MacWilliams held roles as a Senior Fellow at the Center on Global Energy Policy at Columbia University, and a Senior Advisor at the Boston Consulting Group. During the Obama Administration, Mr. MacWilliams served as Associate Deputy Secretary and CRO of the U.S. Department of Energy. His extensive experience in finance, investment, and banking was gained while at JP Morgan Chase and Goldman Sachs, among other firms, and as an entrepreneur.
“Probius is positioned to transform how biological data impacts the digital age as no company has,” said John MacWilliams. “I am excited to lend my experience to assure that the company has every opportunity to succeed in its mission of fueling the AI revolution to improve human health.”
About Janis Naeve
Janis Naeve joined Cota Capital, which led the $8 Million Series A investment in Probius, in 2022. She previously helped establish and lead Amgen Ventures, which nurtured an investment portfolio encompassing digital health, healthcare IT, and advanced data analytics. In addition to her nearly two decades in biotech investing, Naeve served as the Director of Business Development for several biotech firms.
“Probius is focused on bringing real game-changing bioanalytical tools to market,” said Janis Naeve. “Understanding complex problems in human health requires as much information as possible. Probius’ digital representations of the complexity of biology are designed to speed therapeutics to market. It’s exciting to have input on what could be the next big breakthrough.”
About Probius
Probius, headquartered in Fremont, CA, is a deep-tech company bridging the data gap between biology and AI, illuminating new opportunities for the way biomedical research and healthcare are practiced. By combining physics, mathematics, and biological data, the company will usher in a new age of AI-enabled biological research and decentralized predictive healthcare. Built on ten years of R&D, with over $15M of financial support from the DoD and early-stage investors, the company is commencing the commercialization of its revolutionary products.
For more information: https://www.probius.bio/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
